Pamela A. Trail

8.6k total citations
61 papers, 3.7k citations indexed

About

Pamela A. Trail is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Pamela A. Trail has authored 61 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 28 papers in Molecular Biology and 27 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Pamela A. Trail's work include Monoclonal and Polyclonal Antibodies Research (24 papers), Peptidase Inhibition and Analysis (16 papers) and HER2/EGFR in Cancer Research (11 papers). Pamela A. Trail is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (24 papers), Peptidase Inhibition and Analysis (16 papers) and HER2/EGFR in Cancer Research (11 papers). Pamela A. Trail collaborates with scholars based in United States, Germany and Canada. Pamela A. Trail's co-authors include David Willner, Shirley J. Lasch, Raymond A. Firestone, Sandra J. Hofstead, Gene M. Dubowchik, Scott M. Wilhelm, I Taylor, Lila Adnane, Arris J. Henderson and Ingegerd Hellström and has published in prestigious journals such as Science, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Pamela A. Trail

60 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pamela A. Trail United States 29 1.7k 1.5k 1.2k 521 474 61 3.7k
Johanna Lahdenranta United States 23 2.0k 1.2× 1.4k 0.9× 823 0.7× 618 1.2× 331 0.7× 51 3.6k
André Pèlegrin France 38 1.6k 0.9× 1.5k 1.0× 1.9k 1.6× 397 0.8× 606 1.3× 148 4.4k
Joachim Drevs Germany 29 2.0k 1.2× 1.1k 0.8× 510 0.4× 757 1.5× 124 0.3× 75 3.4k
David C. Blakey United Kingdom 25 1.9k 1.1× 643 0.4× 475 0.4× 593 1.1× 531 1.1× 52 3.6k
Neil I. Goldstein United States 27 2.2k 1.3× 2.1k 1.4× 656 0.5× 499 1.0× 752 1.6× 64 4.3k
Puja Sapra United States 28 1.5k 0.9× 1.1k 0.8× 963 0.8× 337 0.6× 400 0.8× 62 3.1k
Sarajane Ross United States 23 2.0k 1.2× 1.2k 0.8× 883 0.7× 327 0.6× 490 1.0× 37 3.1k
Wijnand Helfrich Netherlands 38 1.7k 1.0× 1.2k 0.8× 998 0.8× 267 0.5× 1.4k 2.9× 114 3.7k
Brunhilde Felding‐Habermann United States 28 2.4k 1.4× 2.0k 1.3× 488 0.4× 1.1k 2.1× 593 1.3× 43 5.4k
Dominic Fan United States 37 2.0k 1.2× 2.0k 1.3× 284 0.2× 755 1.4× 494 1.0× 72 4.1k

Countries citing papers authored by Pamela A. Trail

Since Specialization
Citations

This map shows the geographic impact of Pamela A. Trail's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pamela A. Trail with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pamela A. Trail more than expected).

Fields of papers citing papers by Pamela A. Trail

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pamela A. Trail. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pamela A. Trail. The network helps show where Pamela A. Trail may publish in the future.

Co-authorship network of co-authors of Pamela A. Trail

This figure shows the co-authorship network connecting the top 25 collaborators of Pamela A. Trail. A scholar is included among the top collaborators of Pamela A. Trail based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pamela A. Trail. Pamela A. Trail is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vogl, Annette M., Sarah Herterich, Philipp Cyprys, et al.. (2025). TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile. Molecular Cancer Therapeutics. 24(11). 1685–1700.
2.
3.
Rigamonti, Nicolò, Niina Veitonmäki, Francesca Malvezzi, et al.. (2022). A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression. Cancer Immunology Research. 10(5). 626–640. 18 indexed citations
4.
Rigamonti, Nicolò, Susanne Mangold, Andrea Valeri, et al.. (2020). Abstract 1073: A tumor-targeted CD40 agonistic DARPin® molecule leading to antitumor activity with limited systemic toxicity. Cancer Research. 80(16_Supplement). 1073–1073. 1 indexed citations
5.
Kelly, Marcus P., Carlos Hickey, Sosina Makonnen, et al.. (2017). Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers. Molecular Cancer Therapeutics. 16(7). 1299–1311. 19 indexed citations
6.
Papadopoulos, Kyriakos P., Robin Kate Kelley, Anthony W. Tolcher, et al.. (2015). A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(6). 1348–1355. 59 indexed citations
7.
Jimeno, Antonio, Patricia LoRusso, Robert Matthew Strother, et al.. (2013). Phase I study of REGN421 (R)/SAR153192, a fully-human delta-like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2502–2502. 14 indexed citations
8.
Chesebrough, Jon, Sally‐Ann Ricketts, Margaret H. Veldman-Jones, et al.. (2011). Dual IGF-I/II–Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth. Cancer Research. 71(3). 1029–1040. 105 indexed citations
9.
Schatz, Christoph A., Charlotte Kopitz, Lila Adnane, et al.. (2011). Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9. Molecular Cancer Therapeutics. 11(2). 340–349. 49 indexed citations
10.
Walker, Michael, Dalton King, R. A. Dalterio, et al.. (2004). Monoclonal antibody mediated intracellular targeting of tallysomycin S10b. Bioorganic & Medicinal Chemistry Letters. 14(16). 4323–4327. 14 indexed citations
11.
King, Dalton, et al.. (2003). BR96 conjugates of highly potent anthracyclines. Bioorganic & Medicinal Chemistry Letters. 13(13). 2119–2122. 16 indexed citations
12.
Dubowchik, Gene M., Harold Mastalerz, Michael Walker, et al.. (2002). Doxorubicin immunoconjugates containing bivalent, lysosomally-Cleavable dipeptide linkages. Bioorganic & Medicinal Chemistry Letters. 12(11). 1529–1532. 30 indexed citations
13.
Walker, Michael, Gene M. Dubowchik, Sandra J. Hofstead, Pamela A. Trail, & Raymond A. Firestone. (2002). Synthesis of an immunoconjugate of camptothecin. Bioorganic & Medicinal Chemistry Letters. 12(2). 217–219. 33 indexed citations
14.
Salih, Helmut R., Gary C. Starling, Deryk Loo, et al.. (2000). Constitutive Expression of Functional 4-1BB (CD137) Ligand on Carcinoma Cells. The Journal of Immunology. 165(5). 2903–2910. 70 indexed citations
15.
Trail, Pamela A., David Willner, A. Bianchi, et al.. (1999). Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.. PubMed. 5(11). 3632–8. 32 indexed citations
16.
Siegall, Clay B., et al.. (1995). Immunoconjugates and Immunotoxins for Therapy of Carcinomas. Advances in pharmacology. 33. 349–388. 11 indexed citations
17.
Casazza, Anna Maria, Pamela A. Trail, & K E Hellström. (1994). Drug immunotargeting for carcinomas: A reality at last?. Annals of Oncology. 5(8). 703–708. 6 indexed citations
18.
Trail, Pamela A., David Willner, Shirley J. Lasch, et al.. (1993). Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates. Science. 261(5118). 212–215. 414 indexed citations
19.
Rose, William C., George A. Basler, Pamela A. Trail, et al.. (1990). Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30. Investigational New Drugs. 8(S1). S25–S32. 19 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Johanna Lahdenranta Breakdown of academic impact, for papers by André Pèlegrin Breakdown of academic impact, for papers by Joachim Drevs Breakdown of academic impact, for papers by David C. Blakey Breakdown of academic impact, for papers by Neil I. Goldstein Breakdown of academic impact, for papers by Puja Sapra Breakdown of academic impact, for papers by Sarajane Ross Breakdown of academic impact, for papers by Wijnand Helfrich Breakdown of academic impact, for papers by Brunhilde Felding‐Habermann Breakdown of academic impact, for papers by Dominic Fan
Rankless by CCL
2026